Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDRX30
|
|||
| Drug Name |
Batiraxcept
|
|||
| Synonyms |
AVB-S6-500
Click to Show/Hide
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [1] | |
| Company |
Aravive
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | AXL receptor tyrosine kinase ligand (GAS6) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04729608) A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC). U.S.National Institutes of Health. | |||
| REF 2 | Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500. Clin Transl Sci. 2020 Jan;13(1):204-211. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.